关清华 程岚 旷劲松

    [摘要] 目的 觀察达格列净治疗2型糖尿病肾病的临床效果。 方法 选择2019年1月至2020年1月我院内分泌科收治的120例2型糖尿病肾病患者，随机分为两组，每组各60例。对照组给予缬沙坦，实验组给予达格列净，两组患者均治疗3个月。比较两组治疗前后体质量指数(BMI)、糖化血红蛋白(HbAlc)、血肌酐(Scr)、尿酸(UA)、尿微量白蛋白/尿肌酐比值(UMA/UCr)及不良反应发生情况。 结果 与治疗前相比，除对照组BMI外，两组患者治疗后各项指标均明显改善(P0.05)。 结论 达格列净对糖尿病肾病患者血糖及尿蛋白情况均有改善作用，并可降低体重及尿酸水平，有肾脏保护作用，对糖尿病肾病的疗效优于缬沙坦，值得临床推广。

    [关键词] 糖尿病肾病;2型糖尿病;达格列净;缬沙坦

    [Abstract] Objective To observe the clinical efficacy of dapagliflozin in treating type 2 diabetic nephropathy(T2DN). Methods A total of 120 cases of patients with T2DN admitted to the department of endocrinology of our hospital from January 2019 to January 2020 were selected and randomly divided into the control group(n=60) and the experimental group(n=60). The control group was treated with valsartan， while the experimental group was treated with dapagliflozin. Both groups of patients were treated for 3 months. Body mass index (BMI) ......